Report
Lisdexamfetamine Dimesylate for the Treatment of Attention Deficit Hyperactivity Disorder in Adults With a History of Depression or History of Substance Use Disorder
by Scott H. Kollins, PhD; Sharon Youcha, MD; Robert Lasser, MD, MBA; and Michael E. Thase, MD Dr. Kollins is from Duke ADHD Program, Duke University Medical Center, Durham, North Carolina; Drs. Youcha and Lasser are from Shire Development Inc., Wayne, Pennsylvania; and Dr. Thase is from the Department of Psychiatry, University of Pennsylvania School […]
Mental Healthcare Utilization and Sleep Disturbance: A Pilot Study
by Randy A. Sansone, MD; Howard C. Edwards, MD; and Jeremy S. Forbis, PhD Dr. Sansone is a Professor in the Departments of Psychiatry and Internal Medicine at Wright State University School of Medicine in Dayton, Ohio, and Director of Psychiatry Education at Kettering Medical Center in Kettering, Ohio; Dr. Edwards is a resident in […]
A New Psychosocial Tool for Gaining Patient Understanding and Acceptance of Long-acting Injectable Antipsychotic Therapy
by Robert A. Lasser, MD, MBA; Nina R. Schooler, PhD; Mary Kujawa, MD, PhD; Kathleen Jarboe, PHMCNS-BC; John Docherty, MD; and Peter Weiden, MD Dr. Lasser is with Shire Pharmaceuticals (Dr. Lasser was with Johnson & Johnson at the time of the development of this manuscript); Dr. Schooler is with SUNY Downstate Medical Center, Brooklyn, […]
